NIH extends agreement with BioFocus until end 2012

11:00 EDT 10 Aug 2010 | BioPortfolio

Saffron Walden, UK; 12 July 2010 – BioFocus announced today that the U.S. National Institutes of Health (NIH) have extended their agreement for the operation of the Molecular Libraries Small Molecule Repository (MLSMR) through December 2012. According to the terms of this agreement, BioFocus will be eligible to receive up to $8.6 million (€7.0 million) over the course of the two year extension.

BioFocus runs a compound management facility for a number of industrial and U.S. government customers out of its Compound Focus, Inc. subsidiary in South San Francisco. Home to the MLSMR since 2004, this facility acquires and stores compounds under the NIH contract and distributes these compounds for high-throughput biological screening throughout the NIH’s academic network in the U.S.

“We are pleased that the NIH has exercised its option to extend its long-standing collaboration with BioFocus’ compound management facility for another two years. BioFocus has proven that it consistently delivers a high-quality service across the vast NIH screening center network,” said Onno van de Stolpe, CEO of Galapagos, BioFocus’ parent company.

About the Molecular Libraries Small Molecule Repository (a Roadmap initiative)
The NIH MLSMR collects samples for high throughput biological screening and distributes them to the NIH Molecular Libraries Screening Center Network. MLSMR is a key component of the Molecular Libraries Initiative, a NIH Roadmap project supporting ‘new pathways to discovery in the 21st century’. The project is funded in whole with U.S. federal funds from the National Institutes of Health, Department of Health and Human Services, under contract HHS-N-278-2004-41001C with Compound Focus, Inc.

About BioFocus
BioFocus aims to expand its partners’ drug pipelines by accelerating the gene-to-drug candidate discovery process. This is achieved through a comprehensive discovery platform, which includes target discovery in human primary cells, focused as well as diverse compound libraries, in vitro and cell-based screening, structural biology, medicinal chemistry, ADME/PK services, supported by unique chemogenomic and informatics tools, and compound library acquisition, storage and distribution services. As a service division of Galapagos, BioFocus has over 250 employees based in the UK, the US and Switzerland. More info at:

BioFocus® is a trademarks of Galapagos NV and/or its affiliates © Copyright 2010 Galapagos NV.

12 July 2010 Ref 1008BIOF
Product enquiries BioFocus:
Richard Gordon
Tel: +44 1799 533 500 Email:

Media enquiries Alto Marketing Limited:
Heidi Stenhouse
Tel: +44 1489 557 672 Email:

Product enquiries BioFocus: Richard Gordon Tel: +44 1799 533 500 Email: Media enquiries Alto Marketing Limited: Heidi Stenhouse Tel: +44 1489 557 672 Email: NEXT ARTICLE

More From BioPortfolio on "NIH extends agreement with BioFocus until end 2012"

Quick Search


Relevant Topics

Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...